{"podcast":{"title":"Hematologic Oncology Update","slug":"hematologic-oncology-update-916423","podcast_index_feed_id":916423,"rss_url":"https://feeds.captivate.fm/hematologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/hematologic-oncology","image_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png","author":"Dr. Neil Love","episode_count":161,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.","last_synced_at":"2026-09-26T04:24:25.521627+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423"},"episode":{"title":"Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting","slug":"chronic-lymphocytic-leukemia-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","published_at":"2026-08-05T14:30:00+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","show_page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423","url":"https://hematologic-oncology.captivate.fm/episode/6107-asco2026-cll","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/3f827d02-b7f0-44d2-a52e-7ef3dacd6906.mp3","summary":"Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications","meta_description":"Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including t…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7204,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-lymphocytic-leukemia-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-lymphocytic-leukemia-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}